FDA Approves Belzutifan for Advanced Renal Cell Carcinoma HIF-2 inhibitor indicated for patients who progress after immunotherapy and anti-VEGF Dec 15, 2023
Why Some Myeloma Patients Refuse Stem Cell Transplant Study shows the various factors behind refusal of autologous stem cell transplantation Dec 15, 2023 video
'Exploding' Field of Antibody-Drug Conjugates Makes Inroads in Ovarian Cancer Our panel of experts discuss the latest data from various ongoing trials Dec 14, 2023 video
Andre Braugher's Cancer Dx; Malignancies Rising in Younger Adults; Negative Trials News, features, and commentary about cancer-related issues Dec 14, 2023
FDA OKs Maintenance Option for High-Risk Neuroblastoma Eflornithine approved to reduce relapse risk in both kids and adults Dec 14, 2023
Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma Will results revive ibrutinib role in MCL following withdrawal of accelerated approval? Dec 13, 2023
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease High survival rates observed in patients not normally suitable for transplant Dec 13, 2023
Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial Numerical advantages in OS, PFS fall short of statistical significance Dec 13, 2023
Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
Early Detection Is Key to Higher Cure Rates in Ovarian Cancer "We are not aware of precancer stages for ovarian cancer" Dec 13, 2023
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
One in Five BRCA-Positive Breast Cancer Patients Able to Conceive Disease-free survival comparable between patients who did and did not become pregnant Dec 12, 2023
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments Dec 12, 2023
Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer Domenica Lorusso details the importance of modern radiotherapy in this regimen Dec 12, 2023
Axatilimab Shows Efficacy in Recurrent/Refractory GVHD Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
Emicizumab Safe, Effective, in Infants With Hemophilia A More than half of children in study had no treated bleeds at follow-up of more than 100 weeks Dec 10, 2023
Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer Triplet therapy may surpass benefits of current "pretty active doublet" therapy, expert says Dec 10, 2023
Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease Near complete resolution of pain events in patients, including adolescents Dec 10, 2023
Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancer Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant Dec 10, 2023
Grappling With Our Deadliest Cancer Here are essential steps to improve lung cancer screening Dec 10, 2023
Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
Completely Oral Regimen Effective, Feasible in APL 97% of patients alive and relapse-free at 3 years Dec 10, 2023
Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivors No difference for survival outcomes for annual versus around every 2 years Dec 09, 2023
AI and Breast Cancer Screening; Cancer After Treatment for Sickle Cell Also in TTHealthWatch: mail-in cervical cancer screening kits Dec 09, 2023 podcast
Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer However, the surgery did reduce risk of contralateral breast cancer Dec 09, 2023
Is Omitting Radiation Therapy in Low-Risk Breast Cancer a Good IDEA? Local recurrence rate of 1% at 5 years in women ages 50-69 with genomically low-risk disease Dec 08, 2023
EUS-Guided Gastroenterostomy Better Option for Cancer-Related Duodenal Blockages However, technique and technology are not widespread Dec 08, 2023
Study Supports ADC as a New Option for Endocrine-Resistant Metastatic Breast Cancer Datopotamab deruxtecan was safe and boosted quality of life Dec 08, 2023
Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC But better safety profile versus continued pembrolizumab plus chemotherapy Dec 08, 2023
Milestone Gene Therapies for Sickle Cell Disease Greenlit by FDA Casgevy and Lyfgenia approved for one-time treatment of sickle cell disease Dec 08, 2023
Study 'Underscores' Value of Early Fertility Counseling for Breast Cancer Patients Younger age, embryo/oocyte cryopreservation at diagnosis tied to an increased chance of pregnancy Dec 08, 2023
More Awareness Needed of Heart Events Tied to Breast Cancer Drugs, Experts Say Myriad clinical manifestations of cardiotoxicity must be diagnosed, treated promptly Dec 08, 2023
Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer Promising early results with pembrolizumab, nivolumab but event-free survival data still pending Dec 07, 2023
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients Association strongest in patients with overweight, obesity Dec 07, 2023
